Your browser doesn't support javascript.
loading
SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants
Fiona Tea; Alberto Ospina Stella; Anupriya Aggarwal; David Ross Darley; Deepti Pilli; Daniele Vitale; Vera Merheb; Fiona X. Z. Lee; Philip Cunningham; Gregory J Walker; David A Brown; William D Rawlinson; Sonia R Isaacs; Vennila Mathivanan; Markus Hoffman; Stefan Poehlmann; Dominic E Dwyer; Rebecca Rockett; Vitali Sintchenko; Veronica C Hoad; David O Irving; Gregory J Dore; Iain B Gosbell; Anthony D Kelleher; Gail V Matthews; Fabienne Brilot; Stuart G Turville.
Affiliation
  • Fiona Tea; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Childrens Hospital at Westmead, Sydney, New South Wales, Australia
  • Alberto Ospina Stella; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Anupriya Aggarwal; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • David Ross Darley; St Vincents Hospital, Sydney, New South Wales, Australia and School of Medicine, St Vincents Clinical School, The University of New South Wales, Sydney, New Sou
  • Deepti Pilli; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Childrens Hospital at Westmead, Sydney, New South Wales, Australia
  • Daniele Vitale; Westmead Institute for Medical Research, Sydney, New South Wales, Australia
  • Vera Merheb; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Childrens Hospital at Westmead, Sydney, New South Wales, Australia
  • Fiona X. Z. Lee; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Childrens Hospital at Westmead, Sydney, New South Wales, Australia
  • Philip Cunningham; St Vincents Applied Medical Research, Sydney, New South Wales, Australia
  • Gregory J Walker; University of New South Wales
  • David A Brown; Westmead Institute for Medical Research, Sydney, New South Wales, Australia and New South Wales Health Pathology, Sydney, Australia
  • William D Rawlinson; Prince of Wales Hospital
  • Sonia R Isaacs; New South Wales Health Pathology, Sydney, Australia
  • Vennila Mathivanan; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Markus Hoffman; German Primate Center Infection Biology Unit, Georg-August-University, Goettingen, Germany and Faculty of Biology and Psychology, Georg-August-University, Goett
  • Stefan Poehlmann; German Primate Center Infection Biology Unit, Georg-August-University, Goettingen, Germany and Faculty of Biology and Psychology, Georg-August-University, Goett
  • Dominic E Dwyer; New South Wales Health Pathology and Centre for Infectious Diseases and Microbiology - Public Health, ICPMR and Marie Bashir Institute for Biosecurity, Faculty
  • Rebecca Rockett; Centre for Infectious Diseases & Microbiology - Public Health, New South Wales Health Pathology - ICPMR and Marie Bashir Institute for Biosecurity, Faculty of M
  • Vitali Sintchenko; Centre for Infectious Diseases & Microbiology - Public Health, New South Wales Health Pathology - ICPMR and Marie Bashir Institute for Biosecurity, Faculty of M
  • Veronica C Hoad; Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
  • David O Irving; Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
  • Gregory J Dore; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia and St Vincents Hospital, Sydney, New South Wales, Australia
  • Iain B Gosbell; Australian Red Cross Lifeblood, Melbourne, Victoria, Australia
  • Anthony D Kelleher; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Gail V Matthews; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia and St Vincents Hospital, Sydney, New South Wales, Australia
  • Fabienne Brilot; The University of Sydney
  • Stuart G Turville; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
Preprint in English | medRxiv | ID: ppmedrxiv-20248567
ABSTRACT
The SARS-CoV-2 antibody neutralization response and its evasion by emerging viral variants are unknown. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 RT-PCR-confirmed COVID-19 individuals with detailed demographics and followed up to seven months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization were associated with COVID-19 severity. A subgroup of high responders maintained high neutralizing responses over time, representing ideal convalescent plasma therapy donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal plasma donors and vaccine monitoring and design. One Sentence SummaryNeutralizing antibody responses to SARS-CoV-2 are sustained, associated with COVID19 severity, and evaded by emerging viral variants
License
cc_no
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint